Title : From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.

Pub. Date : 2013 Oct

PMID : 24041919






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The recent US Food and Drug Administration (FDA) approval of the serotonin (5-hydroxytryptamine, 5-HT) 5-HT2C receptor agonist lorcaserin for the treatment of obesity represents a new therapeutic drug class available to the clinic. Serotonin 5-hydroxytryptamine receptor 2C Homo sapiens
2 The recent US Food and Drug Administration (FDA) approval of the serotonin (5-hydroxytryptamine, 5-HT) 5-HT2C receptor agonist lorcaserin for the treatment of obesity represents a new therapeutic drug class available to the clinic. Serotonin 5-hydroxytryptamine receptor 2C Homo sapiens